American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 13-17 , July 2008

Effect of Intensive Insulin Therapy and Pentastarch Resuscitation on Acute Kidney Injury in Severe Sepsis

  • George Thomas, MD, MPH

      Affiliations

    • Caritas St. Elizabeth's Medical Center, Boston, Massachusetts
    • ,
  • Ethan M. Balk, MD, MPH

      Affiliations

    • Tufts Medical Center, Boston, Massachusetts
    • ,
  • Bertrand L. Jaber, MD, MS

      Affiliations

    • Caritas St. Elizabeth's Medical Center, Boston, Massachusetts
    • Corresponding Author InformationAddress correspondence to Bertrand L. Jaber, MD, MS, Caritas St. Elizabeth's Medical Center, Medicine, Division of Nephrology, 736 Cambridge St, Boston, MA 02135.

References 

  1. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004;351:159–169
  2. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. 2001;17:107–124
  3. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–1367
  4. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–461
  5. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992–1000
  6. Wang LC, Lei S, Wu YC, et al. Intensive insulin therapy in critically ill patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006;18:748–750
  7. Bellomo R. Fluid resuscitation: Colloids vs. crystalloids. Blood Purif. 2002;20:239–242
  8. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2007;4:CD000567
  9. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med. 1999;25:258–268
  10. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: Acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008;51:491–503
  11. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115:2277–2286
  12. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J Clin Invest. 2004;114:1187–1195
  13. Thomas G, Rojas MC, Epstein SK, Balk EM, Liangos O, Jaber BL. Insulin therapy and acute kidney injury in critically ill patients: A systematic review. Nephrol Dial Transplant. 2007;22:2849–2855
  14. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: Benefit versus harm. Diabetes. 2006;55:3151–3159
  15. Van den Berghe G. Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l. Diabetologia. 2008;51:911–915
  16. The George Institute. Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR STUDY). http://www.clinicaltrials.gov/ct/show/NCT00220987Accessed March 10, 2008
  17. Bellomo R, Egi M. Glycemic control in the intensive care unit: Why we should wait for NICE-SUGAR. Mayo Clin Proc. 2005;80:1546–1548
  18. GLUCONTROL Study: Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients. http://www.clinicaltrials.gov/ct/show/NCT00107601Accessed March 10, 2008
  19. Malhotra A. Intensive insulin in intensive care. N Engl J Med. 2006;354:516–518
  20. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 2003;31:359–366
  21. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA. 2003;290:2041–2047
  22. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes. 2006;55:1096–1105
  23. Ragaller MJ, Theilen H, Koch T. Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol. 2001;12(suppl 17):S33–S39
  24. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet. 1993;342:248–249
  25. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: A retrospective, multicentre analysis. Nephrol Dial Transplant. 1999;14:1517–1520
  26. Himpe D, Van Cauwelaert P, Neels H, et al. Priming solutions for cardiopulmonary bypass: Comparison of three colloids. J Cardiothorac Vasc Anesth. 1991;5:457–466
  27. Dehne MG, Muhling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G. Effect of hydroxyethyl starch solution on kidney function in surgical intensive care patients. Anasthesiol Intensivmed Notfallmed Schmerzther. 1997;32:348–354
  28. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet. 2001;357:911–916
  29. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med. 2008;8:1
  30. De Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med. 2001;111:417–418
  31. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network (AKIN): Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31

 Originally published online as doi:10.1053/j.ajkd.2008.04.008 on June 4, 2008.

PII: S0272-6386(08)00763-4

doi: 10.1053/j.ajkd.2008.04.008

American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 13-17 , July 2008

Article Tools

* Image Usage & Resolution